Literature DB >> 30005767

Breast Cancer Genetics and Indications for Prophylactic Mastectomy.

Helen Krontiras1, Meagan Farmer2, Julie Whatley3.   

Abstract

As more genetic information becomes available to inform breast cancer treatment, screening, and risk-reduction approaches, clinicians must become more knowledgeable about possible genetic testing and prevention strategies, including outcomes, benefits, risks, and limitations. The aim of this article is to define and distinguish high- and moderate-risk breast cancer predisposition genes, summarize the clinical recommendations that may be considered based on the identification of pathogenic variants (mutations) in these genes, and indications for risk-reducing and contralateral prophylactic mastectomy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA; Contralateral prophylactic mastectomy; Genetic counseling; Multigene panel testing; Risk-reducing mastectomy

Mesh:

Year:  2018        PMID: 30005767     DOI: 10.1016/j.suc.2018.03.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  3 in total

Review 1.  Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

Authors:  Ismail Jatoi
Journal:  Eur J Breast Health       Date:  2018-10-01

2.  Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.

Authors:  Sara Mirandola; Francesca Pellini; Eleonora Granuzzo; Maya Lorenzi; Beatrice Accordini; Maurizio Ulgelmo; Alessandra Invento; Davide Lombardi; Marina Caldana; Giovanni Paolo Pollini
Journal:  Int J Surg Case Rep       Date:  2019-04-05

3.  Revisiting the indication for prophylactic contralateral mastectomy in patients with Li-Fraumeni syndrome and breast cancer. Case report

Authors:  Ximena Briceño-Morales; Clara Briceño-Morales; Silvia Inés Guerrero-Macías; Ana María Pedroza-Durán; Raúl Alexis Súarez-Rodríguez
Journal:  Rev Colomb Obstet Ginecol       Date:  2021-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.